These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9498459)

  • 1. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.
    Zackin R; Marschner I; Andersen J; Cowles MK; De Gruttola V; Hammer S; Fischl M; Cotton D
    J Infect Dis; 1998 Mar; 177(3):761-5. PubMed ID: 9498459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How frequently should viral load be monitored to evaluate antiretroviral therapies in AIDS clinical trials?
    Wu H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):97-9. PubMed ID: 9928739
    [No Abstract]   [Full Text] [Related]  

  • 3. Virologic and regimen termination surrogate end points in AIDS clinical trials.
    Gilbert PB; DeGruttola V; Hammer SM; Kuritzkes DR
    JAMA; 2001 Feb; 285(6):777-84. PubMed ID: 11176916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the short-, middle- and long-term viral load responses for comparing estimated dynamic parameters.
    Huang Y
    Biom J; 2007 Jun; 49(3):429-40. PubMed ID: 17623347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.
    Flandre P; Pinçon C; Aboulker JP; Brun-Vézinet F; Pialoux G; Raffi F; Descamps D
    HIV Clin Trials; 2006; 7(3):116-24. PubMed ID: 16880168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M; Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study.
    Kamp W; Schokker J; Cambridge E; De Jong S; Schuurman R; De Groot T; Boucher CA
    Antivir Ther; 1999; 4(2):101-7. PubMed ID: 10682155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 load quantitation: a 17-year perspective.
    Holodniy M
    J Infect Dis; 2006 Sep; 194 Suppl 1():S38-44. PubMed ID: 16921471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
    Welles SL; Jackson JB; Yen-Lieberman B; Demeter L; Japour AJ; Smeaton LM; Johnson VA; Kuritzkes DR; D'Aquila RT; Reichelderfer PA; Richman DD; Reichman R; Fischl M; Dolin R; Coombs RW; Kahn JO; McLaren C; Todd J; Kwok S; Crumpacker CS
    J Infect Dis; 1996 Oct; 174(4):696-703. PubMed ID: 8843205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
    Coombs RW; Welles SL; Hooper C; Reichelderfer PS; D'Aquila RT; Japour AJ; Johnson VA; Kuritzkes DR; Richman DD; Kwok S; Todd J; Jackson JB; DeGruttola V; Crumpacker CS; Kahn J
    J Infect Dis; 1996 Oct; 174(4):704-12. PubMed ID: 8843206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for early antiretroviral therapy in patients with CD4 cell counts > 500 cells/mm3.
    Soriano V; Gómez-Cano M; Mas A; Villalba N; Bravo R; González-Lahoz J
    Antivir Ther; 1996 Dec; 1(4):264-5. PubMed ID: 11324829
    [No Abstract]   [Full Text] [Related]  

  • 13. Considerations in the selection of end points for AIDS clinical trials.
    Amato DA; Lagakos SW
    J Acquir Immune Defic Syndr (1988); 1990; 3 Suppl 2():S64-8. PubMed ID: 2121954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobile phones to improve HIV treatment adherence.
    Chi BH; Stringer JS
    Lancet; 2010 Nov; 376(9755):1807-8. PubMed ID: 21071073
    [No Abstract]   [Full Text] [Related]  

  • 15. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
    Tierney C; Lathey JL; Christopherson C; Bettendorf DM; D'Aquila RT; Hammer SM; Katzenstein DA
    J Infect Dis; 2003 Jan; 187(1):144-8. PubMed ID: 12508159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.
    Wu H; Ding AA
    Biometrics; 1999 Jun; 55(2):410-8. PubMed ID: 11318194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 19. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death.
    Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):139-45. PubMed ID: 10682131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.